当前位置: X-MOL 学术Curr. Opin. Endocrinol. Diabetes Obes. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real?
Current Opinion in Endocrinology, Diabetes and Obesity ( IF 2.6 ) Pub Date : 2020-06-01 , DOI: 10.1097/med.0000000000000545
Larissa G Gomes 1 , Berenice B Mendonca , Tânia A S S Bachega
Affiliation  

Data on the long-term cardio-metabolic outcomes classical congenital adrenal hyperplasia (CAH) patients have been published with controversial results. Conventional treatment recommends hydrocortisone during childhood; and short and/or long-acting glucocorticoid during adulthood, associated or not with mineralocorticoid, in an attempt to simulate normal cortisol secretion and to normalize androgen excess. However, the balance between glucocorticoid over or undertreatment is very challenging, and patients frequently oscillate between hypercortisolism or hyperandrogenism. Considering these data, we reviewed the frequency of metabolic syndrome components and other cardiovascular risk factors in CAH.

中文翻译:

经典先天性肾上腺皮质增生患者的长期心血管代谢结果:这种风险是真的吗?

已发表有关经典先天性肾上腺皮质增生(CAH)患者长期心血管代谢结果的数据,但结果存在争议。常规治疗建议在儿童时期使用氢化可的松。以及在成年期短和/或长效糖皮质激素,不论是否与盐皮质激素有关,以试图模拟正常的皮质醇分泌并正常化雄激素。但是,糖皮质激素过度使用或治疗不足之间的平衡非常具有挑战性,并且患者经常在皮质醇过多症或雄激素过多症之间振荡。考虑到这些数据,我们回顾了CAH中代谢综合征成分和其他心血管危险因素的发生频率。
更新日期:2020-05-22
down
wechat
bug